Skip to main content

Advertisement

Table 1 Characteristics of patients before and after glutathione treatment (n = 29)

From: Efficacy of glutathione for the treatment of nonalcoholic fatty liver disease: an open-label, single-arm, multicenter, pilot study

  Before treatment After treatment P-value
Age (year) 56.0 ± 13.3 -
Male/female (n) 14/15 -
Dyslipidemia (%) 24 (82.8) -
Statin (%) 12 (41.4) -
Diabetes (%) 14 (48.3) -
BMI (kg/m2) 26.5 ± 3.9 26.5 ± 3.9 0.32
FBS (mg/dL) 118.4 ± 34.3 120.0 ± 27.8 0.24
IRI (μU/mL) 23.1 ± 29.8 23.4 ± 33.8 0.38
HbA1c (%) 6.37 ± 1.18 6.46 ± 1.23 0.016
HDL cholesterol (mg/dL) 55.2 ± 16.3 55.0 ± 15.4 0.32
LDL cholesterol (mg/dL) 114.0 ± 28.8 111.3 ± 28.0 0.08
Triglycerides (mg/dL) 195.2 ± 135.9 163.6 ± 121.9 0.007
NEFA (μEq/L) 651.2 ± 242.5 533.5 ± 209.7 0.013
AST (IU/L) 46.7 ± 17.2 47.6 ± 21.2 0.39
ALT (IU/L) 68.9 ± 36.1 58.1 ± 33.5 0.014
GGT (IU/L) 70.4 ± 46.5 66.6 ± 47.5 0.29
Ferritin (ng/mL) 219.8 ± 150.8 194.4 ± 139.2 0.015
Platelet count (×104 /μL) 20.8 ± 5.7 20.9 ± 5.3 0.30
Type IV collagen 7 s 5.08 ± 1.95 4.84 ± 1.34 0.40
Glutathione in protein fraction (μM) 1.42 ± 0.87 0.93 ± 0.63 0.010
Glutathione in deproteinized fraction (μM) 0.025 ± 0.040 0.019 ± 0.024 0.27
CAP (db/m) 295.7 ± 44.9 285.4 ± 48.8 0.07
LSM (kPa) 9.94 ± 4.93 9.24 ± 4.48 0.16
  1. Data are expressed as mean ± standard deviation. BMI body mass index, FBS fasting blood sugar, IRI immunoreactive insulin, HBA1c, hemoglobin A1c, HDL cholesterol high-density lipoprotein cholesterol, LDL cholesterol low-density lipoprotein cholesterol, NEFA non-esterified fatty acid, AST aspartate aminotransferase, ALT alanine aminotransferase, GGT γ-glutamyl transpeptidase, CAP controlled attenuation parameter, LSM liver stiffness measurement